Spyre Therapeutics (SYRE) Return on Equity (2016 - 2025)
Historic Return on Equity for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2025 value amounting to 0.33%.
- Spyre Therapeutics' Return on Equity rose 2900.0% to 0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33%, marking a year-over-year increase of 2900.0%. This contributed to the annual value of 0.59% for FY2024, which is 23000.0% up from last year.
- Latest data reveals that Spyre Therapeutics reported Return on Equity of 0.33% as of Q3 2025, which was up 2900.0% from 0.44% recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Return on Equity registered a high of 11.04% during Q4 2023, and its lowest value of 2.17% during Q1 2024.
- Over the past 5 years, Spyre Therapeutics' median Return on Equity value was 0.61% (recorded in 2024), while the average stood at 0.07%.
- In the last 5 years, Spyre Therapeutics' Return on Equity soared by 124600bps in 2023 and then crashed by -115300bps in 2024.
- Over the past 5 years, Spyre Therapeutics' Return on Equity (Quarter) stood at 0.71% in 2021, then crashed by -101bps to 1.42% in 2022, then soared by 876bps to 11.04% in 2023, then tumbled by -104bps to 0.49% in 2024, then soared by 34bps to 0.33% in 2025.
- Its last three reported values are 0.33% in Q3 2025, 0.44% for Q2 2025, and 0.42% during Q1 2025.